As of August 21, 2026, a clinical trial registered as NCT05714085 is listed as recruiting on ClinicalTrials.gov. The study, titled "Efficacy, Safety, and Pharmacokinetics of Vericiguat in Pediatric Participants With Heart Failure Due to Left Ventricular Systolic Dysfunction (MK-1242-036)," is designated Phase 2/3.
Note that the event data provided pertains to vericiguat, not nesiritide. No trial update information regarding nesiritide was included in this event record. The trial as described investigates vericiguat's efficacy, safety, and pharmacokinetics specifically in pediatric participants who have heart failure caused by left ventricular systolic dysfunction.
The current status of this trial is recruiting, meaning it is actively enrolling participants at this stage. No results have been reported as part of this update, and no outcome data should be inferred from the recruiting status alone. The trial identifier and further details can be found through the associated ClinicalTrials.gov record.
Readers interested in background information on nesiritide, including its regulatory status as an unapproved research compound, can consult the compound overview for additional context.